...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Tissue Engineering >Effect of recombinant human platelet-derived growth factor-BB-coated sutures on Achilles tendon healing in a rat model: A histological and biomechanical study
【24h】

Effect of recombinant human platelet-derived growth factor-BB-coated sutures on Achilles tendon healing in a rat model: A histological and biomechanical study

机译：重组人血小板衍生生长因子-BB涂层缝合线对大鼠跟腱愈合的影响：组织学和生物力学研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Repairing tendon injuries with recombinant human platelet-derived growth factor-BB has potential for improving surgical outcomes. Augmentation of sutures, a critical component of surgical tendon repair, by coating with growth factors may provide a clinically useful therapeutic device for improving tendon repair. Therefore, the purpose of this study was to (a) coat Vicryl sutures with a defined dose of recombinant human platelet-derived growth factor-BB without additional coating excipients (e.g. gelatin), (b) quantify the recombinant human platelet-derived growth factor-BB released from the suture, and (c) use the recombinant human platelet-derived growth factor-BB-coated sutures to enhance tendon repair in a rat Achilles tendon transection model. Methods: Vicryl sutures were coated with 0, 0.3, 1.0, and 10.0 mg/mL concentrations of recombinant human platelet-derived growth factor-BB using a dip-coating process. In vitro release was quantified by an enzyme-linked immunosorbent assay. Acutely transected rat Achilles tendons were repaired using one of the four suture groups (n = 12 per group). Four weeks following repair, the tensile biomechanical and histological (i.e. collagen organization and angiogenesis) properties were determined. Results: A dose-dependent bolus release of recombinant human platelet-derived growth factor-BB occurred within the first hour in vitro, followed by a gradual release over 48 h. There was a significant increase in ultimate tensile strength (p < 0.01) in the two highest recombinant human platelet-derived growth factor-BB dose groups (1.9 ± 0.5 and 2.1 ± 0.5 MPa) relative to controls (1.0 ± 0.2 MPa). The modulus significantly increased (p = 0.031) with the highest recombinant human platelet-derived growth factor-BB dose group (7.2 ± 3.8 MPa) relative to all other groups (control: 3.5 ± 0.9 MPa). No significant differences were identified for the maximum load or stiffness. The histological collagen and angiogenesis scores were comparable in all groups, although there was a trend for improved collagen organization in the recombinant human platelet-derived growth factor-BB-treated groups (p = 0.054). Conclusions: The results of this study suggest that recombinant human platelet-derived growth factor-BB can be used to reproducibly coat Vicryl sutures and improve remodeling in a rat Achilles tendon transection model by significantly decreasing the resulting cross-sectional area, thus improving the material properties of the repaired tendon.
机译：目的：用重组人血小板源性生长因子-BB修复肌腱损伤具有改善手术效果的潜力。通过用生长因子包被来增强缝合线，这是外科手术腱修复的关键组成部分，可为改善腱修复提供临床上有用的治疗装置。因此，本研究的目的是（a）用限定剂量的重组人血小板衍生生长因子-BB包被Vicryl缝线，而无需额外的包衣赋形剂（例如明胶），（b）定量重组人血小板衍生生长因子-BB从缝合线中释放出来，（c）使用重组人血小板衍生生长因子-BB涂层缝合线增强大鼠跟腱横断模型中的腱修复。方法：采用浸涂法将Vicryl缝线分别涂有0、0.3、1.0和10.0 mg / mL浓度的重组人血小板衍生生长因子BB。通过酶联免疫吸附测定定量体外释放。使用四个缝合线组之一（每组n = 12）修复急性切断的大鼠跟腱。修复后四周，确定拉伸生物力学和组织学（即胶原组织和血管生成）特性。结果：重组人血小板源性生长因子-BB的剂量依赖性推注释放发生在体外的第一个小时内，然后在48小时内逐渐释放。相对于对照组（1.0±0.2 MPa），两个最高的重组人血小板衍生生长因子-BB剂量组（1.9±0.5和2.1±0.5 MPa）的极限抗张强度（p <0.01）显着增加。相对于所有其他组（对照组：3.5±0.9 MPa），最高的重组人血小板衍生生长因子-BB剂量组（7.2±3.8 MPa）使模量显着增加（p = 0.031）。没有发现最大载荷或刚度的显着差异。尽管在重组人血小板衍生生长因子-BB治疗组中有改善胶原组织的趋势（p = 0.054），但所有组的组织学胶原和血管生成评分均相当。结论：这项研究的结果表明，重组人血小板源性生长因子-BB可通过显着减小所产生的横截面面积，从而可重现性地包裹Vicryl缝线并改善大鼠跟腱横断模型中的重塑，从而改善了材料修复的肌腱的特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号